Generic Application Quality Showing Signs Of Improvement
Executive Summary
US FDA’s monthly refuse-to-receive numbers for ANDAs are down early in FY 2017, suggesting that sponsor have an increased understanding of the agency’s standards.
You may also be interested in...
US FDA Wants To Predict ANDA Complete Response Responses
Generic industry, FDA discuss potential ways to increase transparency so agency can better estimate when – and even whether – an ANDA receiving a complete response will be returned.
US FDA Wants To Predict ANDA Complete Response Responses
Generic industry, FDA discuss potential ways to increase transparency so agency can better estimate when – and even whether – an ANDA receiving a complete response will be returned.
Generic Drug Review At US FDA: Has Submission Rush Ended Or Just Paused?
Excitement to get a 10-month ANDA review may have waned in January as submissions plummet, but can approvals keep up?